The Renal Medulla and Hypertension
肾髓质和高血压
基本信息
- 批准号:7673973
- 负责人:
- 金额:$ 33.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-01 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAngiotensin IIAnimalsAntihypertensive AgentsAttenuatedBilirubinBiliverdin reductaseBiliverdineBlood PressureBuffersCarbon MonoxideCathetersCellsChronicCultured CellsDietDuct (organ) structureEnzymesGenerationsGenomicsGunn RatsHemeHenle&aposs loopHumanHypertensionHypotensionIn VitroInbred SHR RatsIndividualInfusion proceduresIronKidneyLaboratoriesLeadMediatingMolecularMusNADPH OxidaseNatriuresisNitric OxideOxidasesOxidative StressOxygenasesPathogenesisPharmaceutical PreparationsPhysiologicalPhysiologyPlayProductionProtein IsoformsReactive Oxygen SpeciesRenal TissueRenal functionRenovascular HypertensionResearchResistanceRoleSodiumSuperoxidesTechniquesTestingThickTransgenic Micebaseblood pressure regulationfeedingheme oxygenase-1inhibitor/antagonistinsightinterstitialkidney medullamouse modelnovelnovel therapeuticspatient populationpressurepublic health relevanceresearch study
项目摘要
DESCRIPTION (provided by applicant): This project will test the central hypothesis that increased HO-1 in the renal medulla lowers blood pressure in angiotensin II (Ang II) hypertension by inhibiting Ang II induced increases in NADPH oxidase and superoxide production via billirubin and CO dependent mechanisms. This will be accomplished by a combined integrative physiological and in vitro approach. The specific aims of this proposal are 1) To test the hypothesis that chronic decreases in renal medullary HO-1 levels enhance and chronic induction of renal medullary HO-1 attenuates Ang II mediated blunting of renal pressure- natriuresis and lower blood pressure, 2) To test the hypothesis that chronic changes in HO-1 can alter the Ang II mediated increase in NADPH oxidase and superoxide production in the renal medulla, 3) To test the hypothesis that HO-1 metabolites CO and bilirubin are essential in buffering Ang II mediated increases in NADPH oxidase, superoxide production and blood pressure, 4) To test the hypothesis that chronic increases in HO-1 levels specifically in the thick ascending loop of Henle (TALH) can reduce Ang II mediated alterations in renal pressure-natriuresis and lower blood pressure via decreasing Ang II mediated NADPH oxidase activity and superoxide anion production in the TALH. Experiments in this proposal will be performed in mice in which HO inhibitors and inducers of HO-1 will be chronically infused via intrarenal medullary interstitial catheters in mice receiving chronic infusions of Ang II. Experiments in Aim 4 will be conducted on a novel transgenic mouse model in which the human HO-1 isoform is specifically expressed in TALH cells. Experiments in this proposal will be performed in mice in which HO inhibitors or inducers will be chronically infused via intrarenal medullary interstitial catheters in mice receiving chronic infusions of Ang II. Further studies will determine the role of HO-1 and its metabolites, CO and bilirubin, on Ang II-mediated superoxide production in isolated tubule segments and cultured cells. The research proposed in this application is significant because it will provide new insights into the mechanism of how induction of HO-1 in the renal medulla can reduce oxidative stress and lower blood pressure in hypertension. Understanding of the mechanisms underlying the anti-hypertensive actions of HO-1 in the renal medulla may provide novel therapeutic options for certain hypertensive patient populations which are resistant to current therapies. PUBLIC HEALTH RELEVANCE: The research proposed in this application is significant because it will provide new insights into the mechanism of how the kidney can regulate blood pressure and how alterations in kidney function can lead to high blood pressure or hypertension. A better understanding of the how the kidney controls blood pressure may provide an opportunity to develop new drugs to treat people with hypertension who are resistant to current therapies.
描述(由申请人提供):本项目将测试中心假设,即肾髓质中HO-1的增加通过抑制Ang II诱导的NADPH氧化酶和超氧化物产生的增加,通过台球红素和CO依赖机制,降低血管紧张素II (Ang II)高血压患者的血压。这将通过综合生理和体外方法来完成。本研究的具体目的是:1)验证肾髓质HO-1水平的慢性降低可增强和慢性诱导肾髓质HO-1可减弱Ang II介导的肾压钠尿和低血压的钝化;2)验证HO-1的慢性改变可改变Ang II介导的肾髓质NADPH氧化酶和超氧化物生成的增加的假设。3)验证HO-1代谢产物CO和胆红素在缓冲Ang II介导的NADPH氧化酶、超氧化物生成和血压升高中所必需的假说。4)验证慢性升高HO-1水平,特别是在Henle厚升环(TALH)中,通过降低Ang II介导的NADPH氧化酶活性和TALH中超氧阴离子的产生,可以减少Ang II介导的肾压-尿钠和血压降低的改变。本实验将在小鼠中进行,在接受慢性输注Ang II的小鼠中,通过肾内髓间质导管慢性输注HO-1抑制剂和HO-1诱导剂。Aim 4的实验将在一种新的转基因小鼠模型上进行,其中人类HO-1亚型在TALH细胞中特异性表达。本实验将在小鼠中进行,在小鼠中,HO抑制剂或诱导剂将通过肾内髓质间质导管长期输注于长期输注Ang II的小鼠。进一步的研究将确定HO-1及其代谢产物CO和胆红素在分离小管段和培养细胞中Ang ii介导的超氧化物产生中的作用。本应用提出的研究具有重要意义,因为它将为高血压患者诱导肾髓质HO-1减少氧化应激和降低血压的机制提供新的见解。了解肾髓质中HO-1抗高血压作用的机制可能为某些对现有治疗方法有耐药性的高血压患者群体提供新的治疗选择。公共卫生相关性:本应用中提出的研究具有重要意义,因为它将为肾脏如何调节血压的机制以及肾脏功能的改变如何导致高血压或高血压提供新的见解。更好地了解肾脏如何控制血压可能为开发新药提供机会,以治疗对现有疗法有抗药性的高血压患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID E STEC其他文献
DAVID E STEC的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID E STEC', 18)}}的其他基金
Project 1 - Role of Bilirubin in Protection against Cardiometabolic Syndrome in Obesity
项目 1 - 胆红素在预防肥胖症心脏代谢综合征中的作用
- 批准号:
9573136 - 财政年份:
- 资助金额:
$ 33.3万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 33.3万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 33.3万 - 项目类别:
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10707997 - 财政年份:2022
- 资助金额:
$ 33.3万 - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2022
- 资助金额:
$ 33.3万 - 项目类别:
Discovery Grants Program - Individual
Role of Angiotensin II in Bladder Dysfunction
血管紧张素 II 在膀胱功能障碍中的作用
- 批准号:
10555926 - 财政年份:2022
- 资助金额:
$ 33.3万 - 项目类别:
Regulation of nuclear calcium and ROS by Angiotensin II in heart cells. Régulation du calcium et ROS nucléaires par l'angiotensine II dans les cellules cardiaques.
血管紧张素 II 对心脏细胞中核钙和 ROS 的调节。
- 批准号:
RGPIN-2016-04414 - 财政年份:2021
- 资助金额:
$ 33.3万 - 项目类别:
Discovery Grants Program - Individual
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 33.3万 - 项目类别:
Operating Grants
Intratubular Angiotensin II and AT1a Receptors in The Proximal Tubules: Roles in Hypertension and Kidney Injury
近曲小管中的管内血管紧张素 II 和 AT1a 受体:在高血压和肾损伤中的作用
- 批准号:
10164776 - 财政年份:2020
- 资助金额:
$ 33.3万 - 项目类别:
Novel Roles of Mitochondrial Angiotensin II in The Proximal Tubule of The Kidney
线粒体血管紧张素 II 在肾近端小管中的新作用
- 批准号:
10251271 - 财政年份:2020
- 资助金额:
$ 33.3万 - 项目类别:
Metabolic and epigenetic regulation of cancer associated fibroblasts by angiotensin II
血管紧张素 II 对癌症相关成纤维细胞的代谢和表观遗传调控
- 批准号:
440714 - 财政年份:2020
- 资助金额:
$ 33.3万 - 项目类别:
Fellowship Programs